Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS) announced the appointment of Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. to its Board of Directors, focusing on strengthening its leadership as it approaches a pivotal year with key clinical trials. Dr. Perlman, an experienced biotechnology leader, has played significant roles at Genentech and Tularik, while Dr. Quigley has a strong background in oncology drug discovery from Gilead and Bristol-Myers Squibb. Their expertise aims to enhance Arcus's strategy to maximize long-term value for patients and shareholders.

Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options to 20 new employees, totaling 310,500 shares at an exercise price of $29.93. This grant adheres to the 2020 Inducement Plan, approved by the Board of Directors in January 2020, in compliance with NYSE rules. The company is focused on developing advanced therapies for cancer, with four clinical candidates currently under investigation. Etrumadenant, AB680, Domvanalimab, and Zimberelimab represent their innovative approach to addressing unmet medical needs in oncology.

Arcus Biosciences (RCUS) and WuXi Biologics have expanded their strategic partnership to discover anti-CD39 antibodies using WuXi's proprietary technology. This collaboration marks the fourth antibody development program between the two companies. Arcus has exclusive global rights to these antibodies and will handle further development and commercialization. The CD39 axis is critical for tumor immunosuppression, and preclinical data suggest that inhibiting CD39 may enhance anti-tumor immunity. Financial details of the agreement were not disclosed, and no material impact on Arcus’s financial position is anticipated.

Arcus Biosciences (NYSE:RCUS) announced its participation in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 10:30 a.m. Eastern Time. The event will feature a live audio webcast accessible via the Arcus website, with a replay available for two weeks post-event.

The company focuses on oncology and is advancing four clinical candidates: Etrumadenant (AB928), AB680, Domvanalimab (AB154), and Zimberelimab (AB122), targeting significant unmet needs in various cancers.

Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options to ten new employees, totaling 343,000 shares at an exercise price of $21.53, the closing price on November 9, 2020. This grant was made under the 2020 Inducement Plan, approved by the Board of Directors in January 2020, in line with NYSE rules. Arcus is focused on developing innovative cancer therapies and currently has four clinical candidates: Etrumadenant, AB680, Domvanalimab, and Zimberelimab, addressing significant cancer treatment gaps.

Arcus Biosciences (NYSE:RCUS) reported Q3 2020 financial results, revealing revenues of $64.5 million, a substantial increase from $1.8 million in Q3 2019, driven by collaboration with Gilead. The company holds $785 million in cash, expected to fund operations into 2023. R&D expenses grew to $51.8 million from $17.2 million due to increased clinical trial activities. Arcus anticipates significant clinical readouts in 2021, aiming for pivotal trials for its cancer therapies, including zimberelimab and domvanalimab.

Arcus Biosciences (NYSE:RCUS) has partnered with AstraZeneca to evaluate the investigational anti-TIGIT antibody, domvanalimab, in a Phase 3 clinical trial for unresectable Stage III non-small cell lung cancer (NSCLC), using Imfinzi as a combination therapy. The collaboration aims to enhance efficacy and long-term survival rates in NSCLC patients, building on promising data from previous trials. AstraZeneca will lead the trial while both companies share costs and maintain rights to their respective therapies.

Arcus Biosciences, Inc. (NYSE:RCUS) has granted stock options to 17 new employees to purchase a total of 559,000 shares at an exercise price of $19.20, reflecting the closing price on October 8, 2020. This issuance falls under the 2020 Inducement Plan, which was approved by the Board of Directors. The company focuses on developing innovative cancer therapies, with four molecules in clinical trials targeting various cancers, including Etrumadenant and AB680.

Arcus Biosciences (NYSE:RCUS) announced the return of Jennifer Jarrett as Chief Operating Officer, overseeing commercial and administrative operations. Jarrett, who previously helped lead the company's IPO, brings extensive experience in healthcare and finance. CEO Terry Rosen emphasized her role in facilitating Arcus's mission to develop transformative cancer therapies, especially with three molecules potentially entering registrational trials. In conjunction with her appointment, Jarrett received options to purchase 900,000 shares at $17.17 each, part of an inducement grant approved by the board.